J. Kurland

发表

NF-κB1 (p50) Homodimers Contribute to Transcription of thebcl-2 Oncogene*

T. McDonnell, M. Story, R. Meyn, 2001, The Journal of Biological Chemistry.

Protease inhibitors restore radiation‐induced apoptosis to Bcl‐2‐expressing lymphoma cells

R. Meyn, J. Kurland, 2001, International journal of cancer.

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

M. Kudo, P. Galle, J. Furuse, 2022, NEJM evidence.

Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells.

M. Andreeff, R. Meyn, P. Chiao, 2004, Molecular cancer therapeutics.

Inhibition of constitutively activated nuclear factor-κB radiosensitizers human cells

M. Andreeff, R. Meyn, P. Chiao, 2004 .

Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

E. Plimack, M. Voss, P. Sharma, 2014 .

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

J. W. Kim, M. Ikeda, Li‐Tzong Chen, 2022, NEJM evidence.

Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing

S. Tucker, R. Meyn, C. Stevens, 2005 .

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

T. Choueiri, M. Fishman, M. Harrison, 2014 .

Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNARepairActivity

S. Tucker, R. Meyn, C. Stevens, 2005 .

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity

S. Tucker, R. Meyn, C. Stevens, 2005, Clinical Cancer Research.

Translation Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) by Activating c-Jun N-terminal Kinase*

N. K. Sah, T. McDonnell, B. Su, 2003, Journal of Biological Chemistry.

Myc-mediated transcriptional repression by recruitment of histone deacetylase.

W. Tansey, J. Kurland, 2008, Cancer research.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

T. Curiel, M. Rebelatto, N. Segal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.

N. Hanna, J. Baselga, R. Herbst, 2013, European journal of cancer.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

P. Ross-Macdonald, T. Choueiri, M. Fishman, 2016, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Donnell, T. Curiel, M. Rebelatto, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.

H. Kohrt, D. Czerwinski, H. Maecker, 2014 .

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

E. Plimack, M. Voss, P. Sharma, 2014 .

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.

T. Curiel, M. Rebelatto, N. Segal, 2016 .

NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene.

T. McDonnell, M. Story, R. Meyn, 2001, The Journal of biological chemistry.

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

G. Abou-Alfa, Diansong Zhou, R. Kelley, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis.

D. Voehringer, R. Meyn, J. Kurland, 2003, The Journal of biological chemistry.

1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

E. Plimack, M. Voss, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS‐690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically‐Based Pharmacokinetic Simulations

V. Roongta, Zheng Yang, E. Masson, 2013, Journal of clinical pharmacology.

1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL.

T. Choueiri, M. Fishman, M. Harrison, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC).

E. Plimack, M. Voss, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

D. Jäger, H. Wakelee, S. Ou, 2016 .

A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

H. Kohrt, J. Wolchok, F. Hodi, 2013 .

CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma.

J. Wolchok, A. Ribas, F. Hodi, 2012 .

The MEK/ERK Pathway Acts Upstream of NFκB1 (p50) Homodimer Activity and Bcl-2 Expression in a Murine B-Cell Lymphoma Cell Line

D. Voehringer, R. Meyn, J. Kurland, 2003, Journal of Biological Chemistry.

Myc-mediated transcriptional repression by recruitment of histone deacetylase.

W. Tansey, J. Kurland, 2008, Cancer research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Crashing waves of destruction: the cell cycle and APC(Cdh1) regulation of SCF(Skp2).

W. Tansey, J. Kurland, 2004, Cancer cell.